DUBLIN, March 18, 2019 /PRNewswire/ — Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of “Quality, Affordable, Self-Care Products™
Source: www.prnewswire.com
Perrigo Company plc (NYSE: PRGO), the leading provider of OTC health and wellness solutions has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the generic version of Finacea Foam (azelaic acid) 15%. Previously, Perrigo filed a patent litigation suit with Bayer AG for this product, subsequent to which LEO Pharma A/S acquired Finacea Foam (azelaic acid) 15% from Bayer AG and then substituted for Bayer AG as the lead plaintiff in the patent litigation suit concerning the product. As per IQVIA, annual market sales for Finacea Foam were ~$62 million for 12 months ended January 2019.
